Common Contracts
3 similar Exclusive License Agreement contracts by Passage BIO, Inc.
EXCLUSIVE LICENSE AGREEMENT by and between Passage Bio, Inc. and Gemma Biotherapeutics, INC. July 31, 2024Exclusive License Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Exclusive License Agreement (this “Agreement”) is entered into as of July 31, 2024 (the “Effective Date”), by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (“Passage”), with offices at 2005 Market St., 39th Floor, Philadelphia, PA 19103, and Gemma Biotherapeutics, Inc., a Delaware corporation (“Gemma”), with offices at 1831 Delancey Place, Philadelphia, PA 19103. Passage and Gemma may be referred to in this Agreement individually as a “Party” or collectively as the “Parties.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
EXCLUSIVE LICENSE AGREEMENT by and between Passage Bio, Inc. and Gemma Biotherapeutics, INC. July 31, 2024Exclusive License Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
